1. Asano N, Takeshima H, Yamashita S, Takamatsu H, Hattori N, Kubo T, Yoshida A, Kobayashi E, Nakayama R, Matsumoto M, Nakamura M, Ichikawa H, Kawai A, Kondo T and Ushijima T. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. Sci Rep, 9: 20360, 2019. doi:10.1038/s41598-019-56883-0.
2. Yamashita S, Nanjo S, Rehnberg E, Iida N, Takeshima H, Ando T, Maekita T, Sugiyama T and Ushijima T. Distinct DNA methylation targets by aging and chronic inflammation: a pilot study using gastric mucosa infected with Helicobacter pylori. Clin Epigenetics, 11: 191, 2019. doi: 10.1186/s13148-019-0789-8.
3. Hata K, Ito M, Boda T, Kotachi T, Kiso M, Masuda K, Sasaki M, Kuroki K, Yorita N, Nagasaki N, Abduwali M, Tanaka S and Chayama K. Gastric cancer with submucosal invasion after successful Helicobacter pylori eradication: A propensity score-matched analysis of patients with annual patient endoscopic survey. Digestion, 99: 59-65, 2019. doi:10.2169/internalmedicine.3734-19.
4. Masuda K, Urabe Y, Ito M, Ono A, Hayes CN, Nakamura K, Kotachi T, Boda T, Tanaka S and Chayama K. Genomic landscape of epithelium with low-grade atypia on gastric cancer after Helicobacter pylori eradication therapy. J Gastroenterol, 54: 907-915, 2019. doi:10.1007/s12194-019-00518-6.
5. 伊藤公訓, 小刀崇弘, 田中信治, 茶山一彰. 9 除菌後胃癌の臨床的特徴. 臨牀消化器内科, 34(13): 1609-1613, 2019.
6. 小刀崇弘, 伊藤公訓, 田中信治, 茶山一彰. 除菌後早期胃癌の内視鏡的特徴と診断のピットフォール. 胃がんperspective, 10(4): 298-301, 2019.
7. 伊藤公訓. ピロリ菌と胃がん 除菌で予防できる病気に. 中國新聞, 2019年5月1日(水曜日): 9, 2019.
8. 伊藤公訓. 消化器内科 Q ピロリ菌の除菌後に胃炎が再発しました. 日本放送協会編, NHKきょうの健康, NHK出版, 東京, 2019: 114, 2019.
9. 伊藤公訓. 若年者除菌の問題提起を胃がん撲滅戦略につなげる. 「Helicobacter Research」編集委員会編, Helicobacter Research, 先端医学社, 東京, 2019 23(1): 23, 2019.
10. Sugimoto M, Murata M and Kawai T. How long should patients be surveyed for gastric cancer risk after Helicobacter pylori eradication therapy? 10 years is no longer enough. J Gastroenterol, 55: 577-578, 2020. doi:10.1007/s00535-020-01674-y.